Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Recruiting 4Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 6Neuromyelitis Optica 2Recurrence 1Optic Neuritis 1Myelitis, Transverse 1Hemoglobinuria, Paroxysmal 1Demyelinating Diseases 1Atypical Hemolytic Uremic Syndrome 1Adrenal Insufficiency 1

Interventions

rozanolixizumab 8zilucoplan 7ravulizumab 6fludarabine 5efgartigimod alfa 5Cyclophosphamide 5telitacicept 3Prednisone 3inebilizumab 2Rituximab 2Pyridostigmine Bromide 2tofacitinib 1thymoglobulin 1talquetamab 1remibrutinib 1prednylidene 1iptacopan 1eculizumab 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Walk Test 1Therapeutics 1Tacrolimus 1Steroids 1Robotic Surgical Procedures 1Psychodrama 1Prednisolone 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Oxaloacetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Myasthenia Gravis × ravulizumab × 1 year × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

NCT05644561 2026-04-17

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
12 enrolled

Myasthenia Gravis

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting
75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

NCT06967480 2026-02-05

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Recruiting
40 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔